Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 25,005
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12521356 | Compositions and methods for treating pain, inflammation, infection, malaria, and sepsis | 🖼🧊📄§ | 2026-01-13 | 2039-06-04 | 0 | 31 |
| 12522646 | Activin receptor type II chimeras and methods of use thereof | 🖼🧊📄§ | 2026-01-13 | 2042-09-15 | 0 | 31 |
| 12521451 | CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy | 🖼🧊📄§ | 2026-01-13 | 2040-11-07 | 0 | 31 |
| 12521355 | Nanoparticle systems for targeted delivery of CRISPR/Cas13 and methods of using same | 🖼🧊📄§ | 2026-01-13 | 2040-07-13 | 0 | 31 |
| 12521389 | Therapeutic approach to lung disease | 🖼🧊📄§ | 2026-01-13 | 2040-06-12 | 0 | 31 |
| 12521344 | Non-aqueous gel composition | 🖼🧊📄§ | 2026-01-13 | 2043-02-01 | 0 | 31 |
| 12521362 | Agent for treating, preventing, or improving psychiatric and nervous system disorders or symptoms | 🖼🧊📄§ | 2026-01-13 | 2040-09-25 | 0 | 31 |
| 12522631 | Compounds for use in the treatment of liver disease | 🖼🧊📄§ | 2026-01-13 | 2040-08-14 | 0 | 31 |
| 12521446 | Anti-CEACAM5 antibody drug conjugates | 🖼🧊📄§ | 2026-01-13 | 2045-02-26 | 0 | 31 |
| 12521354 | Nanoparticles for targeted non-surgical spaying and neutering | 🖼🧊📄§ | 2026-01-13 | 2042-06-08 | 0 | 31 |
| 12522572 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | 🖼🧊📄§ | 2026-01-13 | 2044-03-27 | 0 | 31 |
| 12521359 | Composition for the treatment of muscle wasting | 🖼🧊📄§ | 2026-01-13 | 2040-06-29 | 0 | 31 |
| 12522640 | IL2 agonists | 🖼🧊📄§ | 2026-01-13 | 2039-07-19 | 0 | 31 |
| 12522628 | Aryl glucoside derivative and use thereof in drug | 🖼🧊📄§ | 2026-01-13 | 2042-10-25 | 0 | 31 |
| 12522666 | CD22 targeting-moiety for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) | 🖼🧊📄§ | 2026-01-13 | 2041-03-11 | 0 | 31 |
| 12521418 | Mesenchymal stromal cell exosomes and uses thereof | 🖼🧊📄§ | 2026-01-13 | 2039-04-26 | 0 | 31 |
| 12522844 | VSV chimeric vectors | 🖼🧊📄§ | 2026-01-13 | 2039-11-22 | 0 | 31 |
| 12521425 | Method of liver cancer treatment with safranal-based formulations | 🖼🧊📄§ | 2026-01-13 | 2039-02-11 | 0 | 31 |
| 12521393 | Cytotoxicity targeting chimeras for CCR2-expressing cells | 🖼🧊📄§ | 2026-01-13 | 2044-02-09 | 0 | 31 |
| 12522600 | Crystal form and salt form of bromine domain protein inhibitor and preparation method therefor | 🖼🧊📄§ | 2026-01-13 | 2041-01-19 | 0 | 31 |
| 12521378 | Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans | 🖼🧊📄§ | 2026-01-13 | 2042-04-28 | 0 | 31 |
| 12522635 | Amyloid peptide variants | 🖼🧊📄§ | 2026-01-13 | 2040-02-24 | 0 | 31 |
| 12522636 | Compositions and methods for delivering CFTR polypeptides | 🖼🧊📄§ | 2026-01-13 | 2040-11-06 | 0 | 31 |
| 12521351 | Delayed release oral pharmaceutical composition | 🖼🧊📄§ | 2026-01-13 | 2044-10-02 | 0 | 31 |
| 12514238 | Animal models of lipid metabolism and methods of treating hyperlipidemia or hyperlipidemia-related diseases | 🖼🧊📄§ | 2026-01-06 | 2041-02-26 | 0 | 31 |
| 12516307 | Modified porcine pancreatic elastase proteins | 🖼🧊📄§ | 2026-01-06 | 2041-08-18 | 0 | 31 |
| 12514871 | Pegylated menaquinol compositions and methods of treatment | 🖼🧊📄§ | 2026-01-06 | 2043-05-26 | 0 | 31 |
| 12514890 | Plant exosomes used for treatment of diseases originating from protein aggregates formed in cells | 🖼🧊📄§ | 2026-01-06 | 2040-07-30 | 0 | 31 |
| 12514884 | Composition for use in the treatment of group-B streptococcus (GBS) infections | 🖼🧊📄§ | 2026-01-06 | 2041-04-21 | 0 | 31 |
| 12516112 | Single-chain chimeric polypeptides and uses thereof | 🖼🧊📄§ | 2026-01-06 | 2044-05-20 | 0 | 31 |
| 12516298 | Gene therapies for lysosomal disorders | 🖼🧊📄§ | 2026-01-06 | 2044-04-26 | 0 | 31 |
| 12516350 | Compositions and methods for selective gene regulation | 🖼🧊📄§ | 2026-01-06 | 2041-11-10 | 0 | 31 |
| 12516070 | Fused ring derivatives and use thereof in pharmacy | 🖼🧊📄§ | 2026-01-06 | 2041-05-18 | 0 | 31 |
| 12514901 | AD36E4ORF1: a therapeutic treatment for Alzheimer's disease | 🖼🧊📄§ | 2026-01-06 | 2040-08-07 | 0 | 31 |
| 12514936 | Composition comprising catalase, preparation method and use thereof and method for killing tumor cells | 🖼🧊📄§ | 2026-01-06 | 2041-09-28 | 0 | 31 |
| 12516306 | Blood glucose stabilizing methods and compositions | 🖼🧊📄§ | 2026-01-06 | 2043-12-12 | 0 | 31 |
| 12516058 | Small-molecule compounds for controlling endosomal toll-like receptors and therapeutic agent for autoimmune diseases using same | 🖼🧊📄§ | 2026-01-06 | 2041-11-25 | 0 | 31 |
| 12516133 | TGFβ/PD-L1 bispecific binding proteins | 🖼🧊📄§ | 2026-01-06 | 2040-11-27 | 0 | 31 |
| 12514908 | Semaglutide depot systems and use thereof | 🖼🧊📄§ | 2026-01-06 | 2042-07-04 | 0 | 31 |
| 12516301 | Optimized SUMF1 genes and expression cassettes and their use | 🖼🧊📄§ | 2026-01-06 | 2040-04-28 | 0 | 31 |
| 12514835 | GABA complex composition | 🖼🧊📄§ | 2026-01-06 | 2042-09-28 | 0 | 31 |
| 12516330 | Viral vectors for treating neurogenic detrusor overactivity | 🖼🧊📄§ | 2026-01-06 | 2045-03-05 | 0 | 31 |
| 12514842 | Use of a benzoate containing composition to treat neurodegenerative disorders | 🖼🧊📄§ | 2026-01-06 | 2040-07-13 | 0 | 31 |
| 12514855 | Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof | 🖼🧊📄§ | 2026-01-06 | 2041-05-17 | 0 | 31 |
| 12516320 | Method of treating breast cancer in a subject by inhibiting NIP7 and a pharmaceutical composition comprising a NIP7 inhibitor | 🖼🧊📄§ | 2026-01-06 | 2043-01-03 | 0 | 31 |
| 12514881 | Use of nocardia rubra cell wall skeleton in regenerative medicine | 🖼🧊📄§ | 2026-01-06 | 2041-01-20 | 0 | 31 |
| 12516132 | Anti-PD-L1 nanobody and Fc fusion protein and application thereof | 🖼🧊📄§ | 2026-01-06 | 2040-06-24 | 0 | 31 |
| 12514833 | Combination of ibuprofen and tramadol for relieving pain | 🖼🧊📄§ | 2026-01-06 | 2040-07-08 | 0 | 31 |
| 12514859 | Pyrazole pyrimidine derivative and uses thereof | 🖼🧊📄§ | 2026-01-06 | 2044-02-05 | 0 | 31 |
| 12516329 | Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell | 🖼🧊📄§ | 2026-01-06 | 2044-12-16 | 0 | 31 |